Advertisement
Table 2 Correlation between SOX2 expression and clinicopathological features of UCB patients
| Parameters Total | Group | Total | SOX2 expression | P value | |
|---|---|---|---|---|---|
| High | Low | ||||
| Gender | Male | 79 (75%) | 59 (56%) | 20 (19%) | 0.747 |
| Female | 27 (25%) | 21 (20%) | 6 (6%) | ||
| Age (years) | < 60 | 37 (35%) | 25 (24%) | 12 (11%) | 0.166 |
| ≥ 60 | 69 (65%) | 55 (52%) | 14 (13%) | ||
| Tumor size (cm) | < 3 cm | 42 (40%) | 27 (25%) | 15 (14%) | 0.030 * |
| ≥ 3 cm | 64 (60%) | 53 (50%) | 11 (10%) | ||
| Multiplicity | Single | 59 (56%) | 42 (40%) | 17 (16%) | 0.251 |
| Multiple | 47 (44%) | 38 (36%) | 9 (8%) | ||
| Histological grade | Low grade | 48 (45%) | 30 (28%) | 18 (17%) | 0.005 ** |
| High grade | 58 (55%) | 50 (47%) | 8 (8%) | ||
| Tumor stage (T) | Ta, T1 | 26 (25%) | 16 (15%) | 10 (9%) | 0.057 |
| T2-T4 | 80 (75%) | 64 (60%) | 16 (15%) | ||
| Lymph nodes metastasis | NO | 92 (87%) | 69 (65%) | 23 (22%) | 0.772 |
| YES | 14 (13%) | 11 (10%) | 3 (3%) | ||
